Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 15;15(12):3191.
doi: 10.3390/cancers15123191.

Diffuse Large B-Cell Lymphoma in the HIV Setting

Maria Huguet  1   2 , José-Tomás Navarro  1   2 , José Moltó  3   4 , Josep-Maria Ribera  1   2 , Gustavo Tapia  5
Affiliations
Review

Diffuse Large B-Cell Lymphoma in the HIV Setting

Maria Huguet et al. Cancers (Basel). .

Abstract

Despite the widespread use of combined antiretroviral therapy (cART) and the subsequent decrease in AIDS-defining cancers, HIV-related lymphomas remain a leading cause of morbidity and mortality in people with HIV (PWH). Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) subtype in PWH. This lymphoma is a heterogeneous disease including morphological variants and molecular subtypes according to the cell of origin or the mutation profile. In the pre-cART era, treatment with standard-dose chemotherapy induced high rates of toxicity and outcomes were very poor. The introduction of cART and the incorporation of infection prophylaxis allowed the use of conventional intensive chemotherapy regimens used in the general population, such as R-CHOP or R-EPOCH. The use of cART during chemotherapy treatment was initially controversial due to the potential risk of adverse drug-drug interactions. However, the availability of current cART regimens with less potential to cause drug interactions and evidence that cART improves survival rates in NHL strongly support the use of cART in PWH with DLBCL. Consequently, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PWH with NHL.

Keywords: HIV; antiretroviral therapy; diffuse large B-cell lymphoma; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Dolcetti R., Gloghini A., Caruso A., Carbone A. A lymphomagenic role for HIV beyond immune suppression? Blood. 2016;127:1403–1409. doi: 10.1182/blood-2015-11-681411. - DOI - PMC - PubMed
    1. Linke-Serinsoz E., Fend F., Quintanilla-Martinez L. Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology viewpoint. Semin. Diagn. Pathol. 2017;34:352–363. doi: 10.1053/j.semdp.2017.04.003. - DOI - PubMed
    1. Centers for Disease Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm. Rep. 1992;41:1–19. - PubMed
    1. Shiels M.S., Pfeiffer R.M., Hall H.I., Li J., Goedert J.J., Morton L.M., Hartge P., Engels E.A. Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and Cervical Cancer in the United States Occurring in Persons with AIDS, 1980–2007. JAMA. 2011;305:1450–1459. doi: 10.1001/jama.2011.396. - DOI - PMC - PubMed
    1. Gopal S., Patel M.R., Yanik E.L., Cole S.R., Achenbach C.J., Napravnik S., Burkholder G.A., Reid E.G., Rodriguez B., Deeks S.G., et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J. Natl. Cancer Inst. 2013;105:1221–1229. doi: 10.1093/jnci/djt158. - DOI - PMC - PubMed